MedTrace Logo

Liothyronine (T3) for Bipolar Depression

NCT00790738 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2015-07-02

Study results available
· View outcomes & findings →

Summary

This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.

Conditions

Interventions

DRUG

Liothyronine (T3)

liothyronine (T3) up to 50 micrograms a day

DRUG

placebo

placebo

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Raphael J Braga, MD · The Zucker Hillside Hospital, North Shore - LIJHS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790738 on ClinicalTrials.gov